ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 283 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $56,032 | -47.4% | 2,206 | -16.0% | 0.00% | -40.0% |
Q4 2022 | $106,511 | +3.4% | 2,626 | -15.5% | 0.01% | -16.7% |
Q3 2022 | $103,000 | -29.5% | 3,108 | -25.1% | 0.01% | -14.3% |
Q2 2022 | $146,000 | -23.6% | 4,150 | 0.0% | 0.01% | -12.5% |
Q1 2022 | $191,000 | -33.4% | 4,150 | -4.1% | 0.01% | -20.0% |
Q4 2021 | $287,000 | -34.2% | 4,328 | -38.1% | 0.01% | -28.6% |
Q3 2021 | $436,000 | -48.6% | 6,991 | -31.7% | 0.01% | -30.0% |
Q2 2021 | $848,000 | +33.3% | 10,236 | +6.7% | 0.02% | +33.3% |
Q1 2021 | $636,000 | -14.5% | 9,592 | -1.1% | 0.02% | -6.2% |
Q4 2020 | $744,000 | +7.7% | 9,701 | -39.6% | 0.02% | +6.7% |
Q3 2020 | $691,000 | -29.7% | 16,050 | -29.5% | 0.02% | -31.8% |
Q2 2020 | $983,000 | +158.7% | 22,754 | +72.1% | 0.02% | +144.4% |
Q1 2020 | $380,000 | -72.8% | 13,221 | -40.0% | 0.01% | -71.0% |
Q4 2019 | $1,397,000 | +125.3% | 22,019 | 0.0% | 0.03% | +121.4% |
Q3 2019 | $620,000 | – | 22,019 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Western Financial Corp/CA | 820,320 | $20,836,128 | 14.83% |
Aquilo Capital Management, LLC | 1,018,474 | $25,869,240 | 10.72% |
Rokos Capital Management LLP | 1,675,921 | $41,537,702 | 3.07% |
COMMODORE CAPITAL LP | 575,000 | $14,605,000 | 2.22% |
Privium Fund Management B.V. | 259,036 | $6,579,514 | 2.21% |
JOHNSON & JOHNSON | 247,598 | $6,288,989 | 2.05% |
WEALTH EFFECTS LLC | 156,810 | $3,982,976 | 2.04% |
M28 Capital Management LP | 67,400 | $1,711,960 | 1.94% |
Evolutionary Tree Capital Management, LLC | 51,878 | $1,317,701 | 1.83% |
Avidity Partners Management LP | 1,741,300 | $44,229,020 | 1.47% |